Project Grant K99CA312836
Award Date 5/15/26
Completion Date 4/30/28
Dollars Obligated $141K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $123,823 to the University of Maryland, Baltimore under the Cancer Research Manpower program (CFDA 93.398) for the period June 1, 2026 through May 31, 2028. This award supports research and training activities focused on characterizing transcriptomic, genomic, and microenvironmental heterogeneity in pancreatic precancerous lesions, specifically intraductal papillary mucinous neoplasms (IPMNs) and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Project Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a Project Grant of $151,263 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, with completion targeted for August 31, 2027. This award supports research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The institutional award provides funding to develop research...
- Federal Grant Award Summary The National Cancer Institute awarded $411,206 to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a project completion date of April 30, 2028. This Project Grant supports the development of small molecule inhibitors targeting the proton-sensing G protein-coupled receptor GPR68 as a novel therapeutic approach for pancreatic ductal adenocarcinoma (PDAC). The research addresses a critical clinical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $682,673 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This award funds research investigating the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease responsible for over 52,000 annual deaths in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $131,933 to The University of Texas MD Anderson Cancer Center under the Cancer Research Manpower program (CFDA 93.398) for the project "Spatial and Functional Profiling Tumor Evolution Trajectories and Microenvironment Interactions of VHL Driven Renal Cancers." The award, effective May 1, 2026 through April 30, 2028, supports research aimed at addressing treatment resistance in clear cell renal cell...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative investigates the molecular mechanisms by which the KEAP1-NRF2 redox-sensing pathway regulates CD8 T cell adaptation to chronic antigen receptor signaling in cancer and chronic infection contexts. The research...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $156,276 to The Regents of the University of California, Berkeley, effective July 1, 2025, through June 30, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at decoding therapeutic, cross-presented tumor antigens in pancreatic cancer to advance cancer vaccine development. The project will employ mass spectrometry-based antigen discovery platforms and...